Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Am J Transplant. 2020 Jul 7;20(12):3620–3630. doi: 10.1111/ajt.16113

Table 3.

Adverse events before transplant

Case 1 Case 2 Case 3 Case 4
CMV None None None None
EBV None None None None
Infections (other) C. Difficile E. Coli UTI and bacteremia None None
Thrombocytopenia None Grade 1 Grade 2 Grade 2
Peripheral neuropathy None None None None
Serious bleeding events None None None None
Thrombotic event None None None Device thrombosis*

CMV, cytomegalovirus tested by PCR; EBV, Epstein-barr virus DNA tested by PCR; UTI, urinary tract infection; thrombocytopenia, CTCAE grading; peripheral neuropathy (self-reported); serious bleeding events (any event requiring transfusion, any overt GI bleeding, any intracranial bleed); thrombotic event, any peripheral or central thrombosis.

*

the patient developed LVAD thrombosis (HeartMate II) complicated by a stroke and expired.

This occurred 5 months after the last cycle of PI therapy.